Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 11/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.69 |
| ▸ | RAB9A | P51151 | 9/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.69 |
| ▸ | NPC1 | O15118 | 8/20 | 0.69 |
| ▸ | GLA | P06280 | 7/20 | 0.69 |
| ▸ | GAA | P10253 | 7/20 | 0.69 |
| ▸ | MAPT | P10636 | 6/20 | 0.69 |
| ▸ | HPGD | P15428 | 6/20 | 0.69 |
| ▸ | PKM | P14618 | 3/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.69 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.69 |
| ▸ | RELA | Q04206 | 3/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.66 |
| ▸ | TP53 | P04637 | 7/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21749198 | 1.00 | SMN1; SMN2 (0.69) | SMN1; SMN2ALDH1A1RAB9AKDM4ENPC1 | |
| SCHEMBL18969781 | 0.82 | KDM4E (1.00) | SMN1; SMN2ALDH1A1RAB9AKDM4ENPC1 | |
| SCHEMBL22822636 | 0.81 | ALDH1A1 (0.76) | SMN1; SMN2ALDH1A1RAB9AKDM4ENPC1 | |
| SCHEMBL2082562 | 0.80 | LMNA (0.57) | SMN1; SMN2ALDH1A1RAB9AKDM4ENPC1 | |
| SCHEMBL29467866 | 0.79 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1RAB9AKDM4ENPC1 | |
| SCHEMBL22822638 | 0.79 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1RAB9AKDM4ENPC1 | |
| SCHEMBL22822619 | 0.78 | KDM4E (1.00) | SMN1; SMN2ALDH1A1RAB9AKDM4ENPC1 | |
| SCHEMBL20777209 | 0.78 | SMN1; SMN2 (0.81) | SMN1; SMN2ALDH1A1RAB9AKDM4ENPC1 | |
| SCHEMBL13621737 | 0.78 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1RAB9AKDM4ENPC1 | |
| SCHEMBL13166604 | 0.77 | SMN1; SMN2 (0.90) | SMN1; SMN2ALDH1A1RAB9AKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200061076-A1 | METHODS OF TREATING LEUKODYSTROPHIES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2020-02-27 | — | — | US | claimed |
| US-20210395203-A1 | DUAL ACTING FKBP12 AND FKBP52 INHIBITORS | PLEX PHARMACEUTICALS, INC. | 2021-12-23 | — | — | US | disclosed |
| US-20200399219-A1 | DUAL ACTING FKBP12 AND FKBP52 INHIBITORS | PLEX PHARMACEUTICALS, INC. | 2020-12-24 | — | — | US | disclosed |
| US-20200061076-A1 | METHODS OF TREATING LEUKODYSTROPHIES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200061076-A1 | METHODS OF TREATING LEUKODYSTROPHIES | SIGMAR1, SPTAN1, TMEM97 | SMN1; SMN2 38/4885ALDH1A1 341/4885RAB9A 3311/4885 |
| US-20200399219-A1 | DUAL ACTING FKBP12 AND FKBP52 INHIBITORS | FKBP2, FKBP1B, FKBP1A | SMN1; SMN2 379/4885ALDH1A1 3559/4885RAB9A 1223/4885 |
| US-20210395203-A1 | DUAL ACTING FKBP12 AND FKBP52 INHIBITORS | FKBP2, FKBP1B, FKBP1A | SMN1; SMN2 379/4885ALDH1A1 3559/4885RAB9A 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.